Tempus

Tempus is an AI-enabled precision medicine company that leverages technology, data, and artificial intelligence to accelerate the discovery of novel targets, predict treatment effectiveness, identify life-saving clinical trials, and diagnose multiple diseases earlier. It provides innovative solutions for healthcare providers, life sciences companies, and patients. For healthcare providers, Tempus offers tools like ONE, an AI-enabled assistant, and NEXT, which identifies and closes gaps in care by surfacing deep insights from multimodal patient data (EHR, lab results, pathology, imaging, clinician notes) and providing precision care pathways at the point of care. It also includes patient tracking, patient lists, and dashboards to monitor insights and notification effectiveness. For life sciences, Tempus assists pharmaceutical and biotech companies with better drug development through its extensive real-world data and algorithmic models. For patients, it helps in finding unique and optimal therapy options. Tempus's technology is built on a vast dataset of de-identified research records and partnerships with academic medical centers and oncology companies. Key offerings include the LENS platform for accessing and analyzing multimodal real-world data and ALGOS, algorithmic models connected to assays for additional insights. Recent developments include the acquisition of Paige for digital pathology, integration of its generative AI co-pilot "David" into EHR platforms, and FDA clearance for AI-powered software like Tempus ECG-Low EF for identifying patients with low left ventricular ejection fraction.